每经AI快讯，1月7日，恒瑞医药（600276）(600276.SH)公告称，公司子公司苏州盛迪亚生物医药有限 公司收到国家药监局通知，批准公司自主研发的1类创新药瑞拉芙普α注射液上市。该药品联合氟尿嘧 啶类和铂类药物用于经充分验证的检测评估PD-L1阳性(CPS≥1)的局部晚期不可切除、复发或转移性胃 及胃食管结合部腺癌的一线治疗。经查询，国内外尚无同类产品获批上市。截至目前，瑞拉芙普α注射 液相关项目累计研发投入约7.11亿元。 ...

瑞银预测，2026年港股IPO数量将达150家至200家，募资额将超3000亿港元。 中资企业蜂拥赴港上市，IPO大单频现，走过火热的2025年，港股IPO在2026年能否延续强劲势头？ "我们认为，港股IPO的热度在今年能够得以延续，基础支撑是存在的。"瑞银集团中国区总裁及瑞银证 券董事长胡知鸷对第一财经表示，中国香港的全球领先国际金融中心地位、港股IPO排队企业数量充足 等，将共同支撑港股IPO继续走热。 瑞银预测，2026年全年，港股上市企业数量将达到150家至200家，募资额有望超过3000亿港元。 从基石投资者参与热度来看，港股IPO项目仍备受追捧。就在本周，MiniMax（稀宇科技）将于1月9日 登录港交所，其吸引了14名基石投资者，包括Aspex、Eastspring、阿里巴巴、易方达等，认购总额约 27.23亿港元，占到募资总额的六成以上。 胡知鸷观察到，此前，部分海外项目发行难度较高，因此需要有一定比例的基石投资者，以增加发行确 定性。"现在这种情况反过来了，是投资人要去争当基石，或者锚定（投资者），核心原因只有一个， 怕抢不到单。" "抢着要做基石" 就在几天前，2025年收官之际，港交所 ...

Market Overview - The Hong Kong stock market experienced its first decline of the year on January 7, with the Hang Seng Index closing at 26,458.95 points, down 251.50 points, a decrease of 0.94% [1][2]. - The Hang Seng Tech Index also fell, closing at 5,738.52 points, down 86.74 points, a decline of 1.49% [2]. Sector Performance - The pharmaceutical and biotechnology sector saw significant gains, with Rongchang Biologics (HK09995) rising over 12%, and other companies like Kailaiying (HK06821) and Tigermed (HK03347) increasing by over 8% [5]. - Rongchang Biologics announced positive clinical trial data for its PD-1/VEGF bispecific antibody RC148, which showed promising efficacy and safety for treating non-small cell lung cancer [5]. - Kangfang Biologics received approval for an important update on its PD-1/VEGF bispecific antibody, indicating significant clinical benefits in treating advanced non-small cell lung cancer [7]. Investment Trends - Southbound funds continued to significantly increase their holdings in Hong Kong stocks, with a net purchase exceeding 9.1 billion HKD by the end of the trading day [8]. - Research from CICC suggests that the Hong Kong stock market is entering a recovery phase, driven by a weaker US dollar and improved domestic liquidity, with a positive outlook for the first half of 2026 [12]. - Guotai Junan Securities anticipates a second round of valuation recovery and performance resurgence in the Hong Kong market in 2026, recommending focus on technology, healthcare, and consumer sectors [12]. Analyst Ratings - Credit Lyonnais maintained a "Outperform" rating for WuXi AppTec, raising the target price to 143.4 HKD, citing expected growth from outsourcing demand and reduced policy uncertainty [10].

Core Viewpoint - The article emphasizes the importance of selecting the right sectors in the A-share market, particularly focusing on emerging industries supported by government policies, such as integrated circuits, new energy, and biomedicine, which are expected to yield significant returns in the coming year [1]. Group 1: Selection Logic - The ten selected stocks are based on three hard standards: policy support, performance certainty, and reasonable valuation [3]. - Policy support is derived from the Ministry of Industry and Information Technology's focus on emerging pillar industries, which will benefit from research subsidies and industrial support [3]. - Performance is guaranteed with expected revenue/net profit growth of at least 20% and a return on equity (ROE) of at least 15% by 2025, with data sourced from company annual reports [3]. - Valuation is considered reasonable if the price-to-earnings (PE) and price-to-book (PB) ratios are below industry averages or at historical lows, providing a safety margin [3]. Group 2: Potential Stocks Analysis - The ten companies span key sectors such as semiconductors, new energy, and biomedicine, each with solid growth logic supported by authoritative data [5]. - Notable companies include: - Northern Huachuang (002371): A leader in semiconductor equipment with a leading domestic market share and a PEG of 1.2 [5]. - China Great Wall (000066): A core player in the Xinchuang hardware sector with a historical low PE of approximately 28 times and strong asset integration expectations [5]. - Desheng Technology (002908): A small-cap stock benefiting from social security services and data rights, with high elasticity expected as policies accelerate in 2026 [5]. Group 3: Core Sector Opportunities - Three key sectors are highlighted for their concentrated policy benefits and strong growth certainty: - Semiconductors and domestic substitution: The Ministry of Industry and Information Technology is promoting industrial foundation reconstruction, benefiting companies like SMIC and Northern Huachuang [6]. - New energy (photovoltaics and energy storage): The national energy work conference aims for an additional 200 million kilowatts of wind and solar installations by 2026, with companies like Longi Green Energy and CATL positioned to benefit [6]. - Biomedicine and innovative drugs: As an emerging pillar industry, stable policies and accelerated overseas expansion are expected to benefit companies like Heng Rui Medicine and Huahai Pharmaceutical [6]. Group 4: Practical Guide for Investors - Investors are advised to utilize three practical methods to seize opportunities without falling into pitfalls: - Verify authoritative information by checking company annual reports on the Shanghai and Shenzhen Stock Exchanges to confirm performance and order status [8]. - Diversify investments by selecting 1-2 stocks from each of the semiconductor, new energy, and biomedicine sectors to mitigate risks [8].

Core Viewpoint - The collaboration between Yiming Oncology and Axion Bio has been terminated due to slow clinical progress by Axion, leading Yiming to regain global rights for two key cancer drugs, IMM2510 and IMM27M, while retaining the previously received $35 million in upfront and milestone payments [2][4]. Group 1: Collaboration Termination - Yiming Oncology announced the termination of its licensing agreement with Axion Bio on January 6, regaining global development and commercialization rights for IMM2510 and IMM27M [2]. - The partnership began in August 2024, with Yiming granting Axion exclusive rights outside Greater China, and Yiming receiving a total of $20 million in upfront and recent payments [2][7]. - The abrupt end of the collaboration was attributed to Axion's slow overseas clinical advancement, as stated by a Yiming representative [2]. Group 2: Financial Implications - Yiming has secured $35 million in non-recurring income, which provides a buffer for cash flow and reinvestment, although future funding needs for global multi-center trials remain a concern [2][9]. - The termination may enhance Yiming's autonomy in clinical and commercial strategies, allowing for accelerated progress based on positive signals from Greater China [2][9]. Group 3: Industry Context - The case highlights the critical constraints of milestone fulfillment and clinical advancement in overseas collaborations, with buyers emphasizing verifiable clinical delivery and clear exit mechanisms [3]. - The termination reflects broader industry challenges, as trust between Chinese innovative drug companies and international partners is being tested, potentially leading to a trend of "returning" or "recalling" collaborations [9][11]. - The surge in business development (BD) transactions from Chinese innovative drug companies, totaling $135.655 billion in 2025, indicates a shift in collaboration models, moving towards more diversified partnerships rather than simple licensing agreements [9][10].

叁、募资规模：整体规模适中，龙头企业表现突出 募资规模分布呈现出"金字塔"结构，大多数企业募资额适中。具体来看，募资额在10亿港元以下的企业占比52%；介于10亿至49.99亿港元之间的占比 35%。尤为值得关注的是，头部企业融资能力强大：宁德时代、赛力斯、三一重工、海天调味等4家企业募资规模突破百亿港元；此外，恒瑞医药、三花 智能、奇瑞汽车等企业的募资额也接近百亿，展现了龙头企业的强劲实力。 2025年，港股市场迎来新一轮内地企业上市热潮。截至12月31日，全年共有118只新股上市，累计募资总额达2611亿港元（不含"绿鞋"）。 其中，111家内地企业成功登陆港股，合计募资2286亿港元，分别占全年新股总量的94%和总募资额的88%，成为驱动港股市场活跃度的核心力量。 壹、上市途径：传统IPO为主流，方式多元化 所有111家内地企业均在港交所主板上市，上市途径呈现多元化格局。其中，高达108家企业通过首次公开募股（IPO）方式挂牌，占比97%，显示其作为 主流方式的地位稳固。此外，有2家企业（找钢集团、图达通）通过De-SPAC方式上市，另有1家企业（东阳光药）采用介绍方式上市，共同构成了市场多 元化的上市 ...

Group 1 - Kangfang Biotech (09926) shares rose over 6% after the approval of an important update to the product label for its PD-1/VEGF bispecific antibody, Ivosidenib, which showed significant clinical benefits in treating advanced non-squamous non-small cell lung cancer [1] - Sunac China (01918) shares fell over 6% as the company reported a contract sales amount of 2.95 billion RMB in December, a year-on-year increase of 68.6%, but with a decrease in average sales price per square meter by 14.4% [1] - Nanshan Aluminum International (02610) saw a nearly 14% increase in shares, attributed to a tight global electrolytic aluminum market, with Indonesia being a key marginal supplier [1] Group 2 - Optical communication stocks rebounded, with Longi Fiber Optic (06869) up 7.46% and Cambridge Technology (06166) up 3.86%, following a significant rise in U.S. optical communication stocks [2] - Hengrui Medicine (01276) shares increased over 2.8% after announcing the approval of two innovative drugs for clinical trials targeting prostate cancer [2] - Cao Cao Travel (02643) shares rose over 7% following the announcement of acquisitions of Yao Travel and Geely Business Travel [2] Group 3 - Hutchison China MediTech (00013) shares increased over 5.3% after announcing positive results from a Phase III trial for a new treatment for autoimmune hemolytic anemia [3] - Geekplus Technology (02590) shares rose slightly by 0.51%, with a report highlighting its stable business model and growth potential due to AI applications [3] Group 4 - Xuan Bamboo Biotech (02575) shares surged over 11.6% after its drug, Pyrotinib, was included in the national medical insurance directory, providing new benefits for advanced breast cancer patients [4] Group 5 - Semiconductor equipment and materials stocks continued to rise, with significant gains for companies like Amkor Technology (AMKR.US) and Lam Research (LRCX.US) [5] - Chinese concept stocks mostly rose, with notable increases for Hesai (HSAI.US) and Pinduoduo (PDD.US), amid a bullish market sentiment [5] - Uber (UBER.US) and Lyft (LYFT.US) saw stock price increases following Nvidia's announcement of advancements in autonomous driving technology [5] Group 6 - Data center cooling stocks experienced a decline, with companies like Modine Manufacturing (MOD.US) and Johnson Controls (JCI.US) facing significant drops [6] - Copper stocks strengthened, with Freeport-McMoRan (FCX.US) and Southern Copper (SCCO.US) showing notable gains as copper futures reached a historic high [6] - The storage sector continued its upward trend, with SanDisk (SNDK.US) achieving a 27.56% increase after launching a new SSD product line [6] Group 7 - Alumis (ALMS.US) shares skyrocketed by 95.31% following positive results from clinical trials for its TYK2 inhibitor targeting psoriasis patients [7] - Tesla (TSLA.US) shares fell over 4.14% as BYD surpassed Tesla in electric vehicle sales in key European markets [7] - Zeta Global (ZETA.US) shares rose 9.83% after announcing a strategic partnership with OpenAI to enhance its product capabilities [7]

Summary of Key Points from the Conference Call Industry Overview - The pharmaceutical industry is experiencing sustained growth, particularly in the innovative drug and device sectors, with leading companies such as WuXi AppTec, Tigermed, United Imaging, and Lepu Medical being highlighted as key players [1][2] - The consumer healthcare sector is expected to recover to positive growth by 2026 after a period of price stabilization, with a focus on underperforming segments like dental and ophthalmic products [1][5] - The brain-computer interface industry is at a critical juncture with technological breakthroughs and clinical validations, supported by policies and the production plans of companies like Neuralink, presenting significant investment opportunities [1][15] Company Recommendations - Recommended companies in the A-share market include: - Heng Rui Medicine - Kelun Pharmaceutical - East China Pharmaceutical - Enhua Pharmaceutical - Teva Biopharmaceuticals - Jingxin Pharmaceutical - Yifan Biopharmaceuticals - WuXi AppTec - Tigermed - Lepu Medical - United Imaging - In the Hong Kong market, recommended companies include: - Hansoh Pharmaceutical - 3SBio - Kelun Biotech - Kintor Pharmaceutical - Yifan Biopharmaceuticals - BeiGene [3] Market Trends and Performance Expectations - The overall strategy for the pharmaceutical sector remains unchanged, with a focus on innovative drugs and devices, expecting a positive shift in performance in Q1 2026 despite a downturn in 2025 [2] - The blood products sector faced significant pressure in 2024, but recovery is anticipated in 2025 due to new product launches [6] - The Chinese medical device market is expected to see optimistic revenue growth in 2026, driven by new product launches and successful bidding processes [11] - United Imaging is projected to have a strong market performance in 2026, benefiting from improved bidding data and expected overseas growth of over 30% [3][12] Specific Sector Insights - The innovative drug sector is actively evolving globally, with China significantly participating in the global R&D landscape, particularly in oncology and metabolic disease treatments [4] - The weight loss and metabolic drug sector is seeing numerous catalysts, with companies like Heng Rui and BoRui focusing on long-acting injection formulations and oral lipid formulations [1][17] - In the autoimmune sector, companies like Yifan, Haizhi, and Kangnuo are highlighted for their oral drugs and long-acting bispecific antibodies, with significant collaborations enhancing their market potential [1][19] Additional Considerations - The pharmacy sector is recommended to focus on leading companies like Yifeng, which is pursuing growth through mergers and acquisitions [7] - The microelectrophysiology market is expected to accelerate revenue growth in 2026 due to the launch of new products and successful bidding processes [10] - The impact of medical insurance negotiations on the GLP-1 market is crucial for increasing penetration rates, with positive policy support for innovative drug development [21]

Group 1: Market Performance - Hong Kong's innovative drug ETF (159570) surged by 3%, with a trading volume exceeding 1.5 billion yuan, following a net inflow of over 62 million yuan today after a previous inflow of 430 million yuan [1][3] - As of January 6, the latest scale of the Hong Kong innovative drug ETF reached over 23.3 billion yuan, leading its peers in the same category [1] Group 2: Economic Signals - Federal Reserve Governor Milan indicated that upcoming economic data may support further interest rate cuts, with expectations of a reduction exceeding 100 basis points this year [3] - Wall Street analysts suggest that if the U.S. unemployment rate rises to 4.7% by December 2025, the Fed may cut rates by 25 basis points this month [3] Group 3: Company Developments - Brain-computer interface "unicorn" Strong Brain Technology completed a financing round of 2 billion yuan, second only to Musk's Neuralink [3] - AI pharmaceutical company Insilico Medicine announced a long-term collaboration with Siveya for anti-tumor drug development, with a total deal value of 888 million USD [3] Group 4: New Drug Approvals - On January 6, BeiGene announced that its self-developed BCL2 inhibitor, Baiyueda® (sotucumab), received conditional approval from the National Medical Products Administration [3] - Shiyao's SYS6017 has initiated Phase II clinical trials for the prevention of shingles [3] Group 5: Investment Insights - Zhongtai Securities predicts that the pharmaceutical sector's opportunities in 2025 will focus on innovation and industry upgrades, with investment strategies continuing into 2026 [5] - The report emphasizes the importance of "innovative drugs and industry chains, demand recovery, and AI" as key investment dimensions [5] Group 6: J.P. Morgan Healthcare Conference - The 44th J.P. Morgan Healthcare Conference is set to take place from January 12 to 15, 2026, in San Francisco, attracting over 8,000 global participants [6] - The conference will feature over 500 listed companies and thousands of startups, focusing on "capital + strategy" discussions [6] Group 7: Industry Trends - Three major trends are highlighted for 2026: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the emergence of new market forces [7] - The report notes that over 20 gene editing companies will showcase breakthroughs in CAR-T and base editing at the conference [7] Group 8: MNC Engagement - Multinational corporations (MNCs) are willing to pay higher prices for innovative drugs from China, with the average total package for drugs purchased from China being 2.76 billion USD, compared to 1.29 billion USD for those from overseas [8] - The willingness of MNCs to pay a premium for Chinese innovations is driven by the need to fill significant pipeline gaps due to impending patent expirations [8] Group 9: Investment Focus - Investment strategies should focus on companies with strong clinical development capabilities and those in popular therapeutic areas such as ADCs, GLP-1, and dual antibodies [11] - Companies that can produce high-quality late-stage clinical assets are likely to attract MNC interest [11] Group 10: Key Therapeutic Areas - The report identifies key therapeutic areas for investment, including ADCs, GLP-1, dual antibodies, and neuroscience, emphasizing the need for innovative platforms and clinical data superiority [12]

Core Viewpoint - Heng Rui Medicine (600276) (01276) has seen its stock price increase by over 4%, currently trading at 77.8 HKD with a transaction volume of 103 million HKD, following the announcement of two innovative drugs receiving approval for clinical trials targeting PSMA-positive prostate cancer [1] Group 1: Drug Approvals - Heng Rui Medicine announced that its two self-developed innovative drugs, HRS-4357 injection and HRS-5041 tablets, have been approved by the National Medical Products Administration for clinical trials [1] - HRS-4357 is a Class 1 radioactive therapeutic drug, and this approval represents an expansion based on its previous single-agent clinical trials [1] - HRS-5041 is a novel androgen receptor protein degradation-targeting small molecule drug, designed to treat prostate cancer by degrading AR proteins, with potential to overcome resistance to existing therapies [1] Group 2: Market Context - The announcement highlights that there are currently no similar products approved for market release, both domestically and internationally [1]